About
Monoclonal Antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyMountain West
Team (18)
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
427
By Phase
PHASE2: 2PHASE1: 2PHASE1/PHASE2: 2
By Status
COMPLETED: 3ACTIVE_NOT_RECRUITING: 2RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06384261Lead Sponsor
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
PHASE2Recruiting
120 participants
Started: Jul 22, 2024 · Completed: Jun 30, 2027
NCT04241549Lead Sponsor
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
PHASE1Completed
6 participants
Started: Mar 25, 2020 · Completed: Jul 19, 2021
NCT04150887Lead Sponsor
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
PHASE1Active, not recruiting
61 participants
Started: Dec 23, 2019 · Completed: May 15, 2026
NCT04023526Lead Sponsor
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
PHASE2Active, not recruiting
103 participants
Started: Jul 29, 2019 · Completed: May 15, 2026
NCT03030612Lead Sponsor
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
PHASE1/PHASE2Completed
38 participants
Started: Dec 31, 2016 · Completed: Aug 31, 2022
Locations (1)
Headquarters
Denver, CO, United States
Map
Loading map...